All In Biotech

Drug Trial Radar · NCT04930809

Single and Multiple Dose Study of VER-01 in Healthy Volunteers

Open-label Study to Evaluate the Pharmacokinetics and Safety of VER-01after Single and Multiple Administration of Different Doses to Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jul 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Nov 25, 2021

Primary completion

Jul 4, 2022

Study completion Jul 11, 2022

Sponsor

Lead sponsor
Vertanical GmbHIndustry
Sponsor type
Industry
First posted
Jun 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Evaluation of pharmacokinetics, tolerability and safety of VER-01 in healthy volunteers

Conditions

  • Healthy

Interventions

  • VER-01Drug

    standardised cannabis extract (containing 21 mg THC per gram drug product)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC] - AUC 0-tTime frame: Group A-D: Day 1; Group E-G: Day 1 and 4
  2. Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC] - AUC 0-∞Time frame: Group A-D: Day 1; Group E-G: Day 1 and 4
  3. Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC] - C maxTime frame: Group A-D: Day 1; Group E-G: Day 1 and 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Medicine in Vienna - Department of Clinical Pharmacology

    Vienna, Austria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.